Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations.

Journal: Frontiers in pharmacology •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Maletin N, Denda N, Paut Kusturica M, et al. (2026). "Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations.". Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1986842